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The ERK MAP kinase signaling cascade plays critical roles in brain development, learning, memory, and
cognition. It has recently been appreciated thatmutation or deletion of elementswithin this signaling pathway
leads to developmental syndromes in humans that are associated with impaired cognitive function and
autism. Here, we review recent studies that provide insight into the biological roles of the ERKs in the brain
that may underlie the cognitive deficits seen in these syndromes.The extracellular signal regulated kinase (ERK) subfamily of
mitogen-activated protein (MAP) kinases comprises the central
elements of one of the most important and best-studied intracel-
lular signaling pathways (Rubinfeld and Seger, 2005). This
pathway mediates the transmission of signals from cell surface
receptors to cytoplasmic and nuclear effectors. Indeed, the
ERKs are activated in response to extracellular stimuli that target
a broad array of receptors (Rubinfeld and Seger, 2005). These
receptors are physically and functionally linked to the ERK
cascade through a diverse group of molecular adapters that
couple them to activation of the GTPases of the Ras family,
Ras and Rap1 (Figure 1). Ligand binding results in the conversion
of Ras-related GTPases into an active conformation, enabling
them to interact with and promote the activation of the raf
kinases, which initiate downstream signaling through the ERK
cascade. The core elements of the ERK signaling pathway
comprise a three-tiered protein kinase cascade including the
raf kinases (B-Raf and Raf1) that phosphorylate and activate the
MAP kinase kinases, MEK1/2, which in turn activate ERK1/2
(Rubinfeld and Seger, 2005). The ERKs phosphorylate a host
of proteins and activate other protein kinases (RSK1–4, MSK1/2,
MNK1/2) that are responsible for the regulation of transcription
and translation. The ERKs and their immediate targets, the
RSKs, are translocated into the nucleus upon activation, allow-
ing the phosphorylation of transcription factors that mediate
the direct regulation of gene expression.
ERK1/2 share 84% sequence identity but little is known about
their isoform-specific actions. Both isoforms are ubiquitously ex-
pressed, are coordinately activated, and have identical substrate
specificity. The relative expression of ERK2 is greater than that of
ERK1, although both are expressed throughout the adult brain.
The ERKs are most highly expressed in neurons, compared to
all other cell types.
In the nervous system, the ERKs are involved in processes as
diverse as the genesis of neural progenitors, learning, and
memory. During development the ERKs respond principally to
growth factors through the activation of receptor tyrosine
kinases. In the mature nervous system, the ERKs are activated
in neurons in response to synaptic activity (Davis and Laroche,
2006). Recently, mutations within elements of the ERK signaling
cascade have been associated with a number of clinical
syndromes that have been collectively termed ‘‘neuro-cardio-
facial-cutaneous (NCFC) syndromes’’ (Bentires-Alj et al., 2006).
Change in gene copy number of ERK signaling elements has
also been described for other clinical phenotypes. New studies
have identified individuals with microdeletions encompassing
the MAPK1 gene that encodes ERK2 in distal chromosome
22q11 who exhibit cognitive deficits and features of the Di-
George syndrome (DGS) spectrum (Shaikh et al., 2007). Further,
a deletion of a locus on chromosome 16 that includes the
MAPK3 gene encoding ERK1 has been associated with autism
and craniofacial anomalies (Kumar et al., 2008; Weiss et al.,
2008). These syndromes frequently include CNS developmental
abnormalities and functional deficits. Collectively, these findings
suggest that genetic alterations involving elements of the ERK
signaling cascade are a significant cause of neurodevelopmental
and cognitive disorders. A number of recent studies have shed
new light on the actions of the ERKs both in neural development
and in the mature brain, providing insight into the biological basis
of the deficits observed in humans in which signaling through the
ERK pathway has been perturbed.
Clinical Syndromes Associated with Altered
ERK Signaling
NCFC Syndromes
A group of related syndromes are characterized by cardiac and
craniofacial abnormalities and include Costello, Noonan,
LEOPARD, and cardio-facio-cutaneous (CFC) syndromes. It
has recently been recognized that the mutated genes act within
a common genetic pathway regulating ERK activation (Figure 1)
(Aoki et al., 2008; Denayer et al., 2008). Importantly, similar
phenotypes arise from both gain of function and loss of function
of a single allele of elements of the ERK pathway (Table 1). Individ-
uals with mutations associated with these syndromes can have
cardiac defects including pulmonic valve stenosis, arrhythmia,
and cardiomyopathy. While the cardiac and craniofacial defects160 Neuron 61, January 29, 2009 ª2009 Elsevier Inc.
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tations of these disorders have not been extensively studied and
less is known about the developmental basis of this part of the
Figure 1. The ERK Signaling Cascade
Table 1. Developmental Disorders with Altered ERK Pathway
Signaling
Syndrome
Mutated
Gene
ERK Signaling
(Gain/Loss
of Function)
Intellectual
Impairment
Costello H-RAS + moderate
Cardio-facio-
cutaneous
K-RAS + moderate-severe
B-RAF + and  moderate-severe
MEK1 + moderate-severe
MEK2 + moderate-severe
Noonan PTPN11/
SHP2
+ variable
K-RAS + variable
SOS1 + variable
LEOPARD PTPN11/
SHP2
 normal-mild
RAF1 + normal-mild
DiGeorge/22q11
deletion
TBX1/
FGF8
 mild-moderate
CRKL  mild-moderate
Distal 22q11
deletion
ERK2  mild-moderate
Neurofibromatosis
type 1
NF1 (mut) + normal-moderate
NF1 (del) + moderate
NF1-like syndrome SPRED1 + mild
Autism (del/
dup 16p11.2)
ERK1 + and  variable
Coffin-Lowry RSK2 () severe
X-linked mental
retardation
RSK4 () severe
phenotype. Noonan syndrome (NS) results from point
mutations in genes encoding upstream elements of
the ERK cascade, namely SHP2, K-Ras, SOS1, and
Raf1 (Gelb and Tartaglia, 2006). This syndrome is
phenotypically diverse, and can include develop-
mental delays and behavioral and learning disabilities
(Lee et al., 2005). Mental retardation is reported in
approximately 25% of patients (Yoshida et al., 2004),
but normal cognitive development is reported as well
(Tartaglia et al., 2002). Classical features include
pulmonic stenosis, short stature, and facial dysmor-
phia. Approximately half of individuals with NS show
gain-of-function mutations in the PTPN11 gene, which
encodes SHP2 (Tartaglia et al., 2002). SHP2 plays crit-
ical roles in fibroblast growth factor receptor (FGFR)
and Trk signaling to the ERKs. Germline mutations in SOS1
have been found in approximately 10% of NS patients, while
RAF1 and K-RAS account for about 4%–15% and 1%–2% of
mutations, respectively. LEOPARD syndrome (lentigines, EKG
abnormalities, ocular hypertelorism, pulmonic stenosis,
abnormal genitalia, retardation of growth, and deafness) arises
from loss-of-function mutations in PTPN11 and K-RAS that are
distinct from those associated with NS, though there is clinical
overlap between the two disorders (Bentires-Alj et al., 2006).
Two recent reports of gain-of-function mutations in RAF1 were
shown to cause Noonan and LEOPARD syndromes, and were
associated with increased ERK activation (Pandit et al., 2007;
Razzaque et al., 2007). CFC has recently been linked to mutations
in K-Ras, B-Raf, and MEK1/2 (Roberts et al., 2006). In CFC
syndrome, mental retardation and developmental delay is found
in over 80% of cases. These patients exhibit structural CNS
anomalies, most prominently reduced cerebral volume and
hypoplasia of the frontal lobe and cerebellum. Costello syndrome
is associated with activating mutations of H-RAS and has a clin-
ical profile similar to CFC (Rauen, 2007; Roberts et al., 2006). The
neurological manifestations of Costello syndrome include frontal
lobe atrophy (40% of patients), cerebellar abnormalities (26% of
patients), and significant mental retardation (Delrue et al., 2003).
Neurofibromatosis type 1 (NF1) arises from mutation or dele-
tion of the NF1 gene encoding neurofibromin, a Ras GTPase
activating protein that acts as a negative regulator of ERK activa-
tion (Ferner, 2007). Over half of individuals with NF1 mutations
have intellectual impairment. Individuals with deletions encom-
passing the NF1 gene exhibit a more severe phenotype and
more profound intellectual impairment (Descheemaeker et al.,
2004) with craniofacial abnormalities (Leppig et al., 1997). The
bases of the impaired neurocognitive functions have been
argued to arise from defects in corticogenesis. NF1 is associated
with macrocephaly, and murine models with analogous NF1
mutations or deletions exhibit increased proliferation of neural
progenitors during embryogenesis that are correlated with ERK
activation (Hegedus et al., 2007). However, recent work by Cui
et al. (2008) have demonstrated an ongoing requirement for
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learning, and memory. They reported that loss of NF1 is associ-
ated with an enhancement of ERK-dependent GABA release,
which contributes to cognitive impairment in murine models of
this disorder.
Recently a new syndromewith a similar clinical presentation has
been described, termed NF1-like syndrome, which results from
loss-of-function mutations in the SPRED1 gene. The SPRED1
gene product normally acts to suppress ERK activation, as does
NF1 (Brems et al., 2007). Thus, loss-of-function mutations in NF1
or SPRED1 result in elevation of ERK pathway activation. These
individuals are also cognitively impaired and macrocephalic and
exhibit facial dysmorphism similar to other NCFC syndromes.
In addition, two genes that are direct targets of the ERK
cascade are associated with X-linked mental retardation.
Coffin-Lowry syndrome results from mutations at Xp22.2, result-
ing in loss of function of RSK2 that is associated with severe
mental retardation (Yntema et al., 1999). Similarly, deletions at
Xq21 that include the RSK4 gene result in a similar phenotype
with profound cognitive impairment (Shalin et al., 2006).
DGS (22q11 Deletion syndrome) is the most common (1/3000)
microdeletion syndrome in humans. DGS is most frequently
associated with loss of a 3 Mb region in chromosome 22q11
(Lindsay, 2001; Scambler, 2000) and has clinical features distinct
from the NCFC disease spectrum. DGS is characterized by
conotruncal cardiac defects and craniofacial anomalies that
may arise from the combinatorial effects of deleting multiple
(30) genes. Importantly, two genes (TBX1 and CRKL) that are
both deleted in the common 3 Mb deletion of DGS act within
a genetic pathway that regulates ERK1/2 signaling in neural crest
cells (Frank et al., 2002; Guris et al., 2006; Moon et al., 2006).
TBX1 acts to regulate FGF8 expression (Wurdak et al., 2006),
and CRKL is an adaptor protein linking the FGFRs (and Trk
receptors) to the ERK cascade (Figure 1). The neurological
features of DGS have been less intensively studied until recently
(Antshel et al., 2005; Schaer et al., 2006). There is a high inci-
dence (45%) of associated psychiatric disease; most commonly,
this is bipolar illness and schizophrenia. Imaging studies have re-
vealed that DGS patients exhibit an approximate 10% decrease
in overall brain volume (Schaer et al., 2006), with a similar loss of
hippocampal volume (Debbane et al., 2006; Deboer et al., 2007),
reduction in cortical thickness, decreased cortical gyrification,
and cerebellar hypoplasia. Simon and colleagues recently re-
ported hypomorphic fronto-parietal cortical white matter tracts
in a group of DGS patients that they associate with nonverbal
cognitive impairment (Simon et al., 2008).
The ERK2 gene, MAPK1, is located on chromosome 22, at
a position distal to the 3 Mb DGS region. A number of unrelated
patients have been identified with deletions of this distal region
of chromosome 22q11 that include the MAPK1 gene, but which
do not physically overlap the DGS deletion (Ben-Shachar et al.,
2008; Rauch et al., 1999; Saitta et al., 1999). Importantly, patients
with distal deletions independently exhibit a spectrum of cranio-
facial abnormalities, cardiac defects, and neurodevelopmental
deficits. These findings suggest that haploinsufficiency for
different elements of the MAPK cascade can result in similar
anatomic and intellectual manifestations, implying sensitivity to
dosage of various elements of the ERK signaling cascade.
In early 2008 there were two independent reports linking
approximately 1% of all cases of autism with deletions or dupli-
cations of a 593 kb region on chromosome 16p11.2. This locus
encompasses the MAPK3 gene that encodes ERK1 (Kumar
et al., 2008; Weiss et al., 2008). Remarkably, these individuals
exhibited dysmorphic facial features and congenital heart
defects that were noted to be similar to those observed in DGS
(Ballif et al., 2007; Ghebranious et al., 2007). While autism is
not a common feature of NCFC syndromes, there are reports
of autism in DGS patients and in those with other syndromes.
Developmental Roles of the ERKs
The discovery of the linkage of the ERK pathway to a number of
CNS syndromes in humans has served to refocus attention on
the underlying actions of these molecules. Remarkably little is
known about the biology of the ERKs in vivo, and indeed many
assumptions about their roles have been contravened by new
data from animals in which the ERKs have been knocked out.
Given the importance of these enzymes, it was surprising that
genetic inactivation of the ERK1 gene, Mapk3, did not result in
an overt phenotype. Knockout of the ERK2 gene, Mapk1,
however, resulted in early embryonic lethality, due principally to
failed placental/trophoblast development (Aouadi et al., 2006).
The recent generation of conditional ERK2 knockouts has
provided new insight into the biology of these enzymes. One of
the central unanswered questions in understanding the roles of
the ERKs in CNS function is to what degree the functional impair-
ments result from abnormalities in development or, alternatively,
reflect an ongoing requirement for ERK activity in synaptic trans-
mission, memory formation, and cognitive function.
Seminal studies in the mouse (Corson et al., 2003), chick (Lunn
et al., 2007), Xenopus (Christen and Slack, 1999), and zebrafish
(Shinya et al., 2001) reported the rather surprising finding that
activated forms of ERK1/2 were spatially restricted to regions
of the embryo that were developing under the influence of FGF,
and that ERK activation could be blocked by pharmacological
inhibition of FGFR function. Prominent regions that develop in
response to FGF action include the branchial arches, migrating
neural crest cells, the midbrain/hindbrain boundary, and devel-
oping forebrain (Figure 2). These observations appeared counter-
intuitive, based on a vast literature describing the broad actions of
the ERKs in conveying signals from the majority of cell surface
receptors. These data provided the first evidence that in vivo
these enzymes might direct development in a highly selective
manner within circumscribed populations of progenitors. The
linkage of ERK activation to FGF signaling has proven to be
a key finding in explaining their developmental roles.
A prominent feature of human syndromes related to mutations
in ERK signaling pathways is the coincidence of CNS, cardiac,
and craniofacial phenotypes. This coincidence arises from the
fact that a subset of neuroepithelial derivatives that are targets
of ERK signaling, neural crest cells, contribute not only to devel-
opment of the nervous system, but to morphogenesis of the
heart, cranium, and face (Figure 2).
ERK1/2 in Neural Crest Development
Gail Martin and colleagues demonstrated the essential actions of
the FGFs in development through genetic regulation of FGF8
expression within the neural crest and neural tube (Meyers
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in the failure to generate a normal complement of neural crest
cells, leading to severe cardiac and craniofacial defects (Meyers
et al., 1998). The phenotypic severity was directly related to the
levels of FGF8. Importantly, disruption of FGF8 expression in the
developing neural tube dramatically affected normal CNS
patterning, leading to the failure to develop a cerebellum, olfac-
tory bulb, and a normal cerebral cortex (Chi et al., 2003). These
morphogenetic events have subsequently been shown to be
reliant upon ERK signaling (Kawauchi et al., 2005). Recently,
Newbern and colleagues have reported that genetic inactivation
of ERK2 in the developing neural crest results in cardiac abnor-
malities and craniofacial defects similar to those observed in the
FGF8 hypomorphs and analogous to phenotypes observed in
humans haploinsufficient for the MAPK1 gene encoding ERK2
(Newbern et al., 2008). Mice in which both ERK isoforms were in-
activated in the developing neural crest displayed a more severe
phenotype. Significantly, similar phenotypes were observed
upon conditional knockout of upstream elements of the ERK
cascade, B-Raf/Raf1 and MEK1/2, as well as knockout of the
transcription factor SRF, which is a direct downstream target
of ERK signaling (Newbern et al., 2008). These data provide clear
evidence that signaling through the ERK cascade is essential for
normal neural crest development.
ERK1/2 in Cortical Development
The actions of the ERKs in the developing brain have only
recently been examined and have revealed a critical role for
ERK2 in cortical development. The first study in which ERK2
was conditionally knocked out of the developing brain has
provided new insight into the biological actions of this enzyme.
Inactivation of ERK2 within cortical neural progenitor cells early
in the neurogenic period results in a thinner, but normally orga-
nized, cortex. The ERK2-deficient mutant cortex contains fewer
neurons but many more astrocytes (Samuels et al., 2008). The
neuronal loss was the result of selective suppression of division
intermediate progenitor cells. The intermediate progenitor cells
are a recently recognized subclass of neural progenitors posi-
tioned within the subventricular zone that undergo symmetric
terminal divisions to generate neurons that then populate all
layers of the developing cortex (Pontious et al., 2008). Previous
work had documented a clear requirement for ERK activity in
FGF-stimulated cortical progenitor differentiation and neurogen-
esis (Menard et al., 2002). The cortical phenotypes in the ERK2
conditional knockout mice are consistent with the action of
the ERKs in conveying FGF signals. FGFs play critical roles in
cortical development and there is good evidence demonstrating
ERK activity as a primary effector of growth factor action. Reduc-
tion of FGF8 expression suppresses neural progenitor prolifera-
tion and increases cell death, resulting in abnormal cortical
structure and patterning (Meyers et al., 1998; Storm et al.,
2006). Similarly, FGF2 null animals exhibit impaired neural
progenitor proliferation, resulting in a 40% reduction in cortical
neurons in the mature frontal and parietal cortex (Zheng et al.,
2004). Analogous phenotypes are observed upon inactivationNeuron 61, January 29, 2009 ª2009 Elsevier Inc. 163
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of FGF2 (Vaccarino et al., 1999) or expression of a constitutively
active FGFR3 (Inglis-Broadgate et al., 2005) resulted in
increased numbers of neurons and cortical volume due to stim-
ulation of neural progenitor proliferation as a direct result of
enhanced ERK signaling (Thomson et al., 2007).
Compelling evidence supporting a role for the ERKs in cortical
neural progenitor proliferation and differentiation has come from
analyzing the effects of mutations of the scaffolding molecules
FRS2 and SHP2 (Figure 1). FRS2 is an essential adaptor protein
linking both the FGFRs and Trks to activation of the ERKs. This
linkage is achieved through receptor-dependent phosphoryla-
tion of FRS2 that allows the formation of a signaling complex
with SHP2 that is necessary for ERK pathway activation (Hadari
et al., 2001). Mice that express mutant forms of FRS2 exhibit
smaller brains, with an approximate 30% reduction in cortical
thickness and fewer neurons (Yamamoto et al., 2005). This effect
was shown to be a consequence of dramatically reduced levels
of ERK activation, specifically resulting in reduced numbers of
proliferating intermediate progenitor cells in the subventricular
zone. These cells have recently entered the spotlight as they
are believed to underlie the evolutionary expansion in size and
the increased surface area and gyrification of the cortex (Pon-
tious et al., 2008). The mutant FRS2 phenotype is very similar
to that observed in mice in which ERK2 was conditionally inacti-
vated during cortical neurogenesis (Samuels et al., 2008). Signif-
icantly, Freda Miller’s lab has recently shown that deletion or
inactivation of the adaptor molecule SHP2, which is mutated in
Noonan and LEOPARD syndromes, in cortical progenitors was
found to inhibit neurogenesis and promote precocious astrocyte
generation through ERK-dependent mechanisms (Gauthier
et al., 2007). Conversely, SHP2 gain-of-function mutations led
to generation of supernumerary neurons and inhibition of glio-
genesis. Conditional inactivation of B-Raf in neural progenitors
resulted in reduced cortical thickness in the postnatal brain
(Zhong et al., 2007) and hypomyelination (Galabova-Kovacs
et al., 2008) phenotypes, which were both associated with
reduced ERK activation.
ERKs in Cellular Survival
It has been widely accepted that the ERKs play essential roles in
neuronal survival, owing to seminal studies by Greenberg and
colleagues (Xia et al., 1995) that were subsequently verified by
many other reports using in vitro models. Recent in vivo studies
examining the effect of genetic inactivation of the ERKs or their
upstream regulators have shown conflicting data. Conditional
inactivation of ERK2 in the developing cortex did not result
in apoptotic neuronal death (Samuels et al., 2008), nor was
cell death observed in mice in which both ERK isoforms were
inactivated (I.S.S. and G.E.L., unpublished data). These findings
are consistent with studies of cortical development by Miller and
colleagues in which MEK (Paquin et al., 2005) and SHP2 (Gauth-
ier et al., 2007) are inactivated in cortical progenitor cells in vivo.
The loss of either protein results in reduced ERK activity within
these cells and causes them to remain undifferentiated until
gliogenic stimuli induce them to differentiate into astrocytes.
The resultant cortices are composed of reduced numbers of
neurons due to altered fate of the progenitors, thereby defining
a role for the ERKs in neuronal differentiation and cell fate deter-
mination rather than survival of these cells (Gauthier et al., 2007;
Paquin et al., 2005). Similarly, conditional knockout of Raf1 and
B-Raf resulted in the loss of ERK signaling leading to reduced
neurogenesis (Zhong et al., 2007) and dysmyelination (Gala-
bova-Kovacs et al., 2008), secondary to impaired progenitor
proliferation, but not apoptosis. Consistent with these findings,
inactivation of both ERK isoforms in B-lymphocyte lineages
was associated with reduced proliferation, but not apoptosis
(Yasuda et al., 2008). Thus far, studies in vivo have not supported
an obligatory role for the ERKs in cellular survival.
ERKs in Memory and Learning
The ERKs are potently activated by synaptic activity, and they
are essential for synaptic plasticity related to learning and
memory formation in mammals and invertebrates (Davis and
Laroche, 2006). Activation of neurotransmitter receptors results
in the initiation of both calcium-dependent and -independent
signaling mechanisms that serve to activate the Ras-related
small GTPases (Thomas and Huganir, 2004). Early work by
Sweatt and colleagues demonstrated an absolute requirement
for ERK activity in induction of LTP (English and Sweatt, 1996),
and subsequent studies have established its necessity for
NMDA-dependent and -independent forms of LTP induction
and maintenance. The molecular basis of these effects is the
subject of intense interest and a number of mechanisms have
been investigated including ERK-dependent regulation of
AMPA receptor insertion into the postsynaptic membrane, phys-
ical remodeling and generation of dendritic spines, Kv4.2 potas-
sium channel function, and the local regulation of protein
synthesis (Thomas and Huganir, 2004). Significantly, the Svo-
boda lab recently reported that glutamate stimulation of a single
dendritic spine resulted in sustained alteration of the volume of
the stimulated spine and subsequent enlargement of neigh-
boring spines that was reliant upon ERK activation, arguing
that such mechanisms underlie the development of LTP (Harvey
et al., 2008). The ERKs also have newly appreciated roles in
memory consolidation. It was recently reported that in the hippo-
campus there is circadian oscillation of ERK activation that is
essential for persistent and stable memory formation (Eckel-Ma-
han et al., 2008), documenting another unexpected level of
complexity in the actions of the ERKs in memory.
New mouse models targeting the ERKs themselves have
provided additional direct evidence of their involvement in
learning and memory. Previous behavioral analysis of mice
treated with inhibitors of ERK activity demonstrated the impor-
tance of ERK signaling in a broad range of memory and learning
tasks (Davis and Laroche, 2006). Thus, it was quite surprising
that analysis of ERK1 knockout mice revealed only a rather
subtle behavioral phenotype (Mazzucchelli et al., 2002; Selcher
et al., 2001). Genetic inactivation of the ERK1 gene results in
hyperactivity (Selcher et al., 2001), and the animals exhibit
a generalized behavioral excitement phenotype with altered
responses to amphetamine (Engel et al., 2008) and cocaine
(Ferguson et al., 2006; Grueter et al., 2006). ERK1 knockout
mice have recently been used as models for mania and bipolar
disorder (Engel et al., 2008). ERK1 null mice are also
reported to have a paradoxical improvement in a striatal-based
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accumbens (Mazzucchelli et al., 2002) that was argued to result
from compensatory actions of ERK2. The recently recognized
genetic linkage of ERK1 to autism suggests that a more exten-
sive behavioral analysis of these animals is in order.
The recent development of conditional ERK2 alleles (Samuels
et al., 2008) and ERK2 hypomorphic mice (Satoh et al., 2007) has
shed new light on the roles of ERK2 in memory and learning.
Samuels and colleagues reported that mice in which ERK2
was knocked out in telencephalic radial glial progenitors exhibit
profound deficits in associative learning in a fear conditioning
assay (Samuels et al., 2008). Satoh et al. generated ERK2 hypo-
morphic mice that exhibit an approximate 30% reduction in
ERK2 levels and an overtly normal brain (Satoh et al., 2007).
Strikingly, these mice exhibit impairment in fear conditioning
and deficits in two spatial memory tasks. These data suggest
that even modest reduction of ERK2 function is sufficient to
result in behavioral impairment. The interpretation of the behav-
ioral phenotypes in hypomorphs, or mice in which the ERKs are
inactivated during development, raises the question of whether
the deficiencies arise from developmental-related structural
perturbations of the brain or are reflective of the acute actions
of these enzymes in synaptic function and plasticity. Analysis
of mice in which ERK2 has been conditionally inactivated at later
developmental times will likely provide insight into the relative
actions of ERK2, and these studies are currently underway in
several laboratories.
Summary
Taken together these findings argue that mammalian develop-
ment is exquisitely sensitive to perturbations in signaling through
the ERK pathway, and either gain of function or loss of function of
a single allele of an ERK pathway gene is sufficient to result in
abnormal brain development and function. The recognition that
the ERKs play very specific roles in CNS development that are
linked to FGF signaling events, and are inexplicably restricted
to distinct populations of neural progenitors, has elucidated
the novel actions of these enzymes in the morphogenesis and
plasticity of the brain. Collectively, these studies underscore
our primitive understanding of the biology of the ERK signaling
pathway in vivo and its unexpected complexity.
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